Keensight Capital to Acquire a Majority Stake in Leading European CRO and CDMO, Symeres, from Gilde Healthcare Private Equity
Keensight Capital to Acquire a Majority Stake in Leading European CRO and CDMO, Symeres, from Gilde Healthcare Private Equity 5/25, 9:00 AM (Source: GlobeNewswire) PARIS, May 25, 2021 (GLOBE NEWSWIRE) -- Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). According to the terms of ...
Source: teletrader.com